IP ALT-803 Followed by SQ ALT-803 for Ovarian Cancer
Phase 2
Completed
- Conditions
- FIGO Stage III and IV Ovarian CancerFIGO Stage III and IV Fallopian Tube CancerFIGO Stage III Primary Peritoneal Cancer
- Interventions
- Biological: ALT-803 IntraperitonealBiological: ALT-803 Subcutaneous
- First Posted Date
- 2017-02-16
- Last Posted Date
- 2023-10-13
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 7
- Registration Number
- NCT03054909
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
QUILT-3.033: Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML
Phase 2
Completed
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Biological: ALT-803
- First Posted Date
- 2017-02-10
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 8
- Registration Number
- NCT03050216
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL
Phase 1
Completed
- Conditions
- Mantle-Cell LymphomaPrimary Mediastinal LymphomaIndolent B Cell LymphomaLymphoplasmacytic LymphomaMultiple MyelomaNon-Hodgkin LymphomaDiffuse Large B Cell LymphomaFollicular Lymphoma
- Interventions
- Biological: Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells
- First Posted Date
- 2017-01-12
- Last Posted Date
- 2022-11-04
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 39
- Registration Number
- NCT03019666
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Glucobrassicin-Brussel Sprout Effect on D10 Phe Metabolism
Phase 1
Completed
- Conditions
- Smoking
- Interventions
- Other: Brussel SproutsDrug: Deuterated Phenanthrene
- First Posted Date
- 2016-12-21
- Last Posted Date
- 2023-02-17
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 39
- Registration Number
- NCT02999399
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies
Phase 2
Terminated
- Conditions
- Natural Killer Cell MalignanciesChronic Myelogenous LeukemiaChronic Lymphocytic LeukemiaAcute Lymphoblastic LeukemiaLarge-cell LymphomaProlymphocytic LeukemiaHodgkin LymphomaBurkitt LymphomaMyelodysplastic SyndromesFollicular Lymphoma
- Interventions
- Biological: Infusion of Treg
- First Posted Date
- 2016-12-14
- Last Posted Date
- 2020-09-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 3
- Registration Number
- NCT02991898
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT
Phase 2
Completed
- Conditions
- Acute Myelogenous Leukemia (AML)Myelodysplastic Syndrome (MDS)
- Interventions
- First Posted Date
- 2016-12-12
- Last Posted Date
- 2023-11-03
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 20
- Registration Number
- NCT02989844
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT
Phase 2
Active, not recruiting
- Conditions
- Hematologic Malignancies
- Interventions
- Biological: Haplo HCT <55 years oldBiological: Haplo HCT ≥55 years oldDrug: GVHD ProphylaxisBiological: Haplo HCT ≥55 and < 65 years oldBiological: Haplo HCT ≥65 and ≤75 years old
- First Posted Date
- 2016-12-09
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 78
- Registration Number
- NCT02988466
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors
- First Posted Date
- 2016-12-09
- Last Posted Date
- 2020-12-10
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 1
- Registration Number
- NCT02988843
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
Early Diagnosis Of Childhood Cerebral ALD
Withdrawn
- Conditions
- Adrenoleukodystrophy
- First Posted Date
- 2016-10-28
- Last Posted Date
- 2018-07-06
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Registration Number
- NCT02948062
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Study of CD133KDEL Toxin in the Treatment for Solid Tumors
Phase 1
Withdrawn
- Conditions
- Solid Tumors
- Interventions
- Drug: CD133KDEL (dCD133KDEL)
- First Posted Date
- 2016-07-27
- Last Posted Date
- 2018-10-03
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Registration Number
- NCT02845414
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
© Copyright 2025. All Rights Reserved by MedPath